Quantitative PK–PD Model-Based Translational Pharmacology of a Novel Kappa Opioid Receptor Antagonist Between Rats and Humans
Journal Title: The AAPS Journal - Year 2011, Vol 13, Issue 4
Abstract
Pharmacokinetic–pharmacodynamic (PK–PD) modeling greatly enables quantitative implementation of the “learn and confirm” paradigm across different stages of drug discovery and development. This work describes the successful prospective application of this concept in the discovery and early development of a novel κ-opioid receptor (KOR) antagonist, PF-04455242, where PK–PD understanding from preclinical biomarker responses enabled successful prediction of the clinical response in a proof of mechanism study. Preclinical data obtained in rats included time course measures of the KOR antagonist (PF-04455242), a KOR agonist (spiradoline), and a KOR-mediated biomarker response (prolactin secretion) in plasma. Clinical data included time course measures of PF-04455242 and prolactin in 24 healthy volunteers following a spiradoline challenge and single oral doses of PF-04455242 (18 and 30 mg). In both species, PF-04455242 successfully reversed spiradoline-induced prolactin response. A competitive antagonism model was developed and implemented within NONMEM to describe the effect of PF-04455242 on spiradoline-induced prolactin elevation in rats and humans. The PK–PD model-based estimate of Ki for PF-04455242 in rats was 414 ng/mL. Accounting for species differences in unbound fraction, in vitro Ki and brain penetration provided a predicted human Ki of 44.4 ng/mL. This prediction was in good agreement with that estimated via the application of the proposed PK–PD model to the clinical data (i.e., 39.2 ng/mL). These results illustrate the utility of the proposed PK–PD model in supporting the quantitative translation of preclinical studies into an accurate clinical expectation. As such, the proposed PK–PD model is useful for supporting the design, selection, and early development of novel KOR antagonists.
Authors and Affiliations
Cheng Chang, Wonkyung Byon, Yifeng Lu, Leslie K. Jacobsen, Lori L. Badura, Aarti Sawant-Basak, Emily Miller, Jing Liu, Sarah Grimwood, Ellen Q. Wang, Tristan S. Maurer
Keywords
Related Articles
- EP ID EP681341
- DOI 10.1208/s12248-011-9296-3
- Views 57
- Downloads 0
On the Incorrect Statistical Calculations of the Kinetica Software Package in Imbalanced Designs
This regulatory note supports the previous findings that suggest that the software package Kinetica, up to version 5.0.10, provides incorrect results for the 90% confidence intervals for the ratio test/reference where th...
Prodrug Approaches for CNS Delivery
Central nervous system (CNS) drug delivery remains a major challenge, despite extensive efforts that have been made to develop novel strategies to overcome obstacles. Prodrugs are bioreversible derivatives of drug molecu...
Pharmacogenomics: The promise of personalized medicine
Commentary: Where and how could biomarkers be used in 2016
Since the beginning of the human genome project there has been considerable speculation about how this resource and the knowledge creation it enabled would change therapeutic discovery, development, and delivery. As the...
Varying polymer architecture to deliver drugs
Variable architecture polymers are of considerable interest for the delivery of therapeutic biopolymers, such as DNA and proteins, to their site of action. Polymers that can respond with a change in conformation to biolo...